Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06831149 · ClinicalTrials.gov registry record · Phase 2
Use of SPY Imaging System to Minimize Fistulas After Hypopharyngeal Reconstruction
A Phase 2 study of Squamous Cell Carcinoma and Pharyngocutaneous Fistula, sponsored by Matthew Spector.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 225
- Enrollment target
- 1
- Study location
NCT06831149 is a Phase 2 study of Squamous Cell Carcinoma and Pharyngocutaneous Fistula that is actively recruiting participants, run by Matthew Spector. The registered enrollment target is 225 participants, above the 99-participant average among 47 other Squamous Cell Carcinoma trials with a reported enrollment target (127% higher). The trial reports 1 study location across 1 state.
The verdict
NCT06831149, a Phase 2 study of Squamous Cell Carcinoma and Pharyngocutaneous Fistula, is actively recruiting participants, sponsored by Matthew Spector.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 225 participants
- Enrollment target
- 1
- Study location
Study Summary
Investigators performing this research want to look at the use of a special imaging process during a specific throat surgery. Using this imaging may help to lower a common complication that called a pharyngocutaneous fistula (PCF). A PCF is a leak in the tube in the throat that helps with breathing and digesting food. The imaging is called the SPY Fluorescence System. This system can identify tissue that is not receiving enough blood. The SPY Fluorescence System uses a special dye, called Indocyanine green (ICG) to better see the tissues that are not receiving enough blood. When tissue does not receive enough blood, it can lead to infection. Infection of tissue in this area of the throat can lead to PCF. The imaging takes about 1 minute and is performed in the operating room during surgery. For this study, the investigators (who are also surgeons) will decide to remove tissue that is identified by the SPY Fluorescence System to have decreased blood flow. They will then continue with the rest of the surgery as usual. The investigators will monitor participants as they recover from surgery to identify any complications that may occur. For this research they are interested in complications during the first month after surgery since this is when PCF usually happens. Investigators will use information that has been documented in the medical records of participants as well as during in-person physical examinations during inpatient recovery and outpatient clinical visits.
Conditions Studied
Interventions
- DEVICE SPY-PHI
- PROCEDURE Removal of pharyngeal mucosa with decreased perfusion will be performed
- DRUG ICG (Indocyanine Green)
Study Locations (1)
Pennsylvania
- UPMC - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 225 participants |
| Start Date | 2025-02-28 |
| Est. Completion | 2030-02-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06831149
The ClinicalTrials.gov registry entry for NCT06831149 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 225 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 99-participant average among 47 other Squamous Cell Carcinoma trials with a reported enrollment target (127% higher). The listed sponsor is Matthew Spector, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Squamous Cell Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which SPY-PHI is the first listed.
NCT06831149 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06831149 about?
NCT06831149 is a clinical study titled "Use of SPY Imaging System to Minimize Fistulas After Hypopharyngeal Reconstruction". Investigators performing this research want to look at the use of a special imaging process during a specific throat surgery. Using this imaging may help to lower a common complication that called a pharyngocutaneous fistula (PCF). A PCF is a leak in the tube in the throat that helps with breathing ...
What is the current status of trial NCT06831149?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 225 participants. The study started on 2025-02-28. Estimated completion is 2030-02-28.
What conditions does trial NCT06831149 study?
This clinical trial studies the following conditions: Squamous Cell Carcinoma, Pharyngocutaneous Fistula.
What interventions are being tested in trial NCT06831149?
The interventions under investigation include: SPY-PHI (DEVICE), Removal of pharyngeal mucosa with decreased perfusion will be performed (PROCEDURE), ICG (Indocyanine Green) (DRUG).
Who is sponsoring clinical trial NCT06831149?
This trial is sponsored by Matthew Spector, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06831149 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Squamous Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Afatinib in Advanced Cutaneous Squamous Cell Carcinoma
RECRUITING · Phase 2
-
Impact of COL7A1 Gene Therapy on SCC Recurrence in RDEB Skin
RECRUITING · Phase 2
-
Toripalimab With Chemotherapy for Sinus Cancer
RECRUITING · Phase 2
-
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
RECRUITING · Phase 2
-
Preoperative Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck
RECRUITING · Phase 2
-
Immunotherapy With Chemotherapy and Chemoradiation for Advanced Squamous Cancer of Nasal Cavity / Paranasal Sinuses (I-NAPA)
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.